DeepMed Research

Piperacillin-Tazobactam

Generic Name: Piperacillin-Tazobactam

Indication: 适用于产β内酰胺酶而对哌拉西林耐药、但对本品敏感的细菌（如大肠埃希菌、克雷伯菌属、柠檬酸杆菌属、肠杆菌属、沙雷菌属、变形杆菌属、摩根菌属、雷极普罗维登菌、铜绿假单胞菌、流感嗜血杆菌、不动杆菌属、葡萄球菌属和拟杆菌属等）所致的下列中、重度感染：

1.肺炎、肺脓肿、脓胸、支气管扩张合并感染和慢性阻塞性肺病继发性感染等下呼吸道感染；

2.创伤或外科伤口继发皮肤软组织感染、蜂窝织炎、皮肤脓肿、糖尿病足感染；

3.胆囊炎、胆管炎、肝脓肿和腹膜炎等腹腔感染；

4.盆腔炎、子宫内膜炎、子宫周围炎、附件炎、盆腔脓肿等生殖系统感染；

5.单纯或复杂性尿路感染。本品用于铜绿假单胞菌严重感染时，应联合氨基糖苷类等其他抗铜绿假单胞菌的药物。

Clinical Trials

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Phase 3

Completed

Conditions: Pancreas Cancer
Pancreatic Diseases
Pancreatic Cancer

Interventions: Drug: Cefoxitin
Drug: Piperacillin-tazobactam

First Posted Date: 2017-09-01

Last Posted Date: 2025-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 958

Registration Number: NCT03269994

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Hackensack Meridian Health / Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States

and more 29 locations

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

Phase 2

Active, not recruiting

Conditions: Intestinal Microbiome
Febrile Neutropenia

Interventions: Drug: cefepime
Drug: Piperacillin-tazobactam

First Posted Date: 2017-03-13

Last Posted Date: 2025-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 347

Registration Number: NCT03078010

Locations: 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

Not Applicable

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Piperacillin-tazobactam combination product
Drug: Meropenem
Drug: Ceftazidime

First Posted Date: 2016-07-21

Last Posted Date: 2021-12-15

Lead Sponsor: University Ghent

Target Recruit Count: 40

Registration Number: NCT02840136

Locations: 🇧🇪
Ghent University, Ghent, Oost-Vlaanderen, Belgium

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock

Phase 3

Completed

Conditions: Septic Shock

Interventions: Drug: MEROPENEM
Drug: PIPERACILLIN-TAZOBACTAM
Drug: CEFEPIME

First Posted Date: 2016-07-01

Last Posted Date: 2025-01-16

Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Target Recruit Count: 119

Registration Number: NCT02820987

Locations: 🇫🇷
Chu Besancon, Besançon, France

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

Phase 2

Completed

Conditions: Urinary Tract Infection Symptomatic
Urinary Tract Infection Complicated
Acute Pyelonephritis

Interventions: Drug: ZTI-01
Drug: Piperacillin-tazobactam

First Posted Date: 2016-04-28

Last Posted Date: 2019-03-07

Lead Sponsor: Nabriva Therapeutics AG

Target Recruit Count: 465

Registration Number: NCT02753946

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia, Influenza, COVID-19

Interventions: Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Eritoran
Drug: Moxifloxacin or Levofloxacin
Drug: Fixed-duration Hydrocortisone
Drug: Extended course macrolide
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Cysteamine
Drug: Imatinib
Drug: Angiotensin Receptor Blockers
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Intermediate dose thromboprophylaxis
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Fixed-duration dexamethasone
Drug: Amoxicillin-clavulanate
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil

First Posted Date: 2016-04-13

Last Posted Date: 2024-07-12

Lead Sponsor: UMC Utrecht

Target Recruit Count: 20000

Registration Number: NCT02735707

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock

Phase 4

Completed

Conditions: Early Phase of Severe Sepsis and Septic Shock

Interventions: Drug: Piperacillin-tazobactam

First Posted Date: 2016-04-06

Last Posted Date: 2017-09-20

Lead Sponsor: Sutep Jaruratanasirikul

Target Recruit Count: 50

Registration Number: NCT02730624

Locations: 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand

Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis

Phase 3

Completed

Conditions: Cholecystitis, Acute

Interventions: Drug: Piperacillin-tazobactam combination product
Drug: Saline solution

First Posted Date: 2015-12-02

Last Posted Date: 2018-03-06

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 100

Registration Number: NCT02619149

Locations: 🇸🇪
Karolinska University Hospital, Center for Digestive Diseases, Stockholm, Sweden

AbioKin - Antibiotic Kinetics

Completed

Conditions: Infection
Critical Illness

Interventions: Drug: Piperacillin-tazobactam combination product
Drug: Linezolid
Drug: Meropenem
Drug: Vancomycin

First Posted Date: 2015-11-20

Last Posted Date: 2021-01-19

Lead Sponsor: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva

Target Recruit Count: 1500

Registration Number: NCT02609646

Locations: 🇮🇹
Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione, Firenze, FI, Italy
🇮🇹
Ospedale San Giovanni di Dio, Orbetello, Grosseto, Italy
🇮🇹
Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1, Lecco, Lombardia, Italy

and more 8 locations

Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)

Phase 1

Conditions: Infection

Interventions: Drug: Piperacillin-tazobactam

First Posted Date: 2015-06-09

Last Posted Date: 2018-04-19

Lead Sponsor: St. Justine's Hospital

Target Recruit Count: 141

Registration Number: NCT02466438

Locations: 🇨🇦
St. Justine's Hospital, Montreal, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy